These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21967627)

  • 1. Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre.
    Fotiadou C; Lazaridou E; Sotiriou E; Ioannides D
    J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1298-303. PubMed ID: 21967627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
    Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
    J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre.
    Warren RB; Brown BC; Lavery D; Griffiths CE
    Br J Dermatol; 2010 Oct; 163(4):859-62. PubMed ID: 20716225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
    Gordon K; Papp K; Poulin Y; Gu Y; Rozzo S; Sasso EH
    J Am Acad Dermatol; 2012 Feb; 66(2):241-51. PubMed ID: 21752491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
    Noda S; Mizuno K; Adachi M
    J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
    Martyn-Simmons CL; Green L; Ash G; Groves RW; Smith CH; Barker JN
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1394-7. PubMed ID: 19573024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
    Ortonne JP; Chimenti S; Reich K; Gniadecki R; Sprøgel P; Unnebrink K; Kupper H; Goldblum O; Thaçi D
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1012-20. PubMed ID: 21214631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness and safety of adalimumab in the treatment of non-reimbursed patients with mild-to-moderate psoriasis.
    Chiu HY; Wang TS; Chang CY; Tsai TF
    J Eur Acad Dermatol Venereol; 2012 Aug; 26(8):991-8. PubMed ID: 21812835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A; Gordon KB; Leonardi CL; Gu Y; Goldblum OM
    J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of Adalimumab in the treatment of moderate to severe palmo-plantar psoriasis: an open label study.
    Richetta AG; Mattozzi C; Giancristoforo S; D'Epiro S; Cantisani C; Macaluso L; Salvi M; Calvieri S
    Clin Ter; 2012; 163(2):e61-6. PubMed ID: 22555836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study.
    Papp K; Ho V; Teixeira HD; Guerette B; Chen K; Lynde C
    J Eur Acad Dermatol Venereol; 2012 Aug; 26(8):1007-13. PubMed ID: 22023702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre.
    López-Ferrer A; Vilarrasa E; Gich IJ; Puig L
    Br J Dermatol; 2013 Nov; 169(5):1141-7. PubMed ID: 23909993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
    Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
    Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis.
    Bagel J
    J Drugs Dermatol; 2011 Apr; 10(4):366-71. PubMed ID: 21455546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
    Papp K; Crowley J; Ortonne JP; Leu J; Okun M; Gupta SR; Gu Y; Langley RG
    Br J Dermatol; 2011 Feb; 164(2):434-41. PubMed ID: 21083543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of obesity on the effectiveness of adalimumab for the treatment of psoriasis: a retrospective study of 30 patients in daily practice.
    Lafuente-Urrez RF; Pérez-Pelegay J
    Eur J Dermatol; 2014; 24(2):217-23. PubMed ID: 24721290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C; Langley RG; Papp K; Tyring SK; Wasel N; Vender R; Unnebrink K; Gupta SR; Valdecantos WC; Bagel J
    Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.